JBPHF (Jacobio Pharmaceuticals Group Co) Forward PE Ratio: 10.98 (As of Jul. 13, 2026)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.35
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Forward PE Ratio?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Forward PE Ratio is 10.98 as of Jul. 13, 2026. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.35. The stock has 6 warning signs investors should review. Among 354 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks better than 78.25% on this metric.

Jacobio Pharmaceuticals Group Co's Forward PE Ratio for today is 10.98.

Jacobio Pharmaceuticals Group Co's PE Ratio without NRI for today is 0.00.

Jacobio Pharmaceuticals Group Co's PE Ratio (TTM) for today is 0.00.


Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Jacobio Pharmaceuticals Group Co Forward PE Ratio Related Terms


Jacobio Pharmaceuticals Group Co Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Forward PE Ratio Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend 2025-12
Forward PE Ratio
315.97

Jacobio Pharmaceuticals Group Co Semi-Annual Data
2025-12
Forward PE Ratio 315.97

JBPHF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Forward PE Ratio falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 10.98 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Forward PE Ratio of 10.98 as of Jul. 13, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #77 out of 354 companies in the Biotechnology industry, placing it in the top 21.8%.
Is Jacobio Pharmaceuticals Group Co's Forward PE Ratio too high?
Jacobio Pharmaceuticals Group Co's current Forward PE Ratio is 10.98. The Biotechnology industry median Forward PE Ratio is 22.13. Jacobio Pharmaceuticals Group Co's value of 10.98 is 50.4% below this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #77 out of 354 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #77 out of 354 companies for Forward PE Ratio. This places Jacobio Pharmaceuticals Group Co in the top 22% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 22.13. Jacobio Pharmaceuticals Group Co's value of 10.98 is 50.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.13, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Forward PE Ratio of 10.98 is 50.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Forward PE Ratio is 10.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Forward PE Ratio of 10.98. The stock's GF Value™ is $0.35, compared to a current price of $0.87 — trading 147.9% above its estimated fair value. The current Forward PE Ratio is 10.98 and 50.4% below the Biotechnology industry median of 22.13. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Forward PE Ratio is 10.98 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 147.9% above its estimated GF Value™ of $0.35.

Key valuation signals for JBPHF:

  • Forward PE Ratio: 10.98
  • GF Value™: $0.35 vs. price of $0.87 (147.9% above fair value)
  • GF Score™: 54/100 with 6 warning signs
  • Industry Position: 50.4% below the Biotechnology median (#77 of 354)

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.35
GF Value